Ozempic, Wegovy, and Your Eyes: Early Signs of Glaucoma You Shouldn’t Ignore

Is it true that popular GLP-1 medications like Ozempic and Wegovy can harm your eyes? In this article, Dr. Narain, a leading retina specialist in San Jose, California, clarifies the facts and reveals surprising benefits for your eye health.

A blue semaglutide injection pen, labeled for subcutaneous use, designed for delivering precise 1 mg doses.

Ozempic, Wegovy, and other GLP-1 receptor agonists have transformed care for people managing diabetes and weight. These medications improve blood sugar control, promote weight loss, and even support heart health. But with their popularity, patients often ask:

• Can Ozempic make me lose my vision?

• Does Wegovy increase the risk of glaucoma or macular degeneration?

• Should I be concerned about my eyes while taking GLP-1 drugs?

Here’s what the latest research reveals, with a special focus on eye health in the San Jose and Gilroy areas.

The Concern: A Rare Vision Condition (NA-AION)

Some early reports suggested a link between GLP-1 drugs and non-arteritic anterior ischemic optic neuropathy (NA-AION). In simple terms, NA-AION is sudden vision loss caused by reduced blood flow to the optic nerve. While concerning, larger and more reliable studies showed:

• Cases of NA-AION in GLP-1 users are extremely rare.

• The risk was not statistically significant compared to non-users. Takeaway: The overwhelming majority of patients taking Ozempic or Wegovy will not experience this type of optic nerve damage.

The Possible Eye Benefits of GLP-1 Medications: Early Signs of Glaucoma

Surprisingly, research suggests GLP-1 medications may actually protect the eyes.

• Glaucoma and Vision Loss: Studies found that patients on GLP-1 drugs had a lower risk of glaucoma-related vision loss.

• Macular Degeneration (AMD): People with age-related macular degeneration who used GLP-1 medications often experienced better outcomes compared to those not on these treatments, early signs of glaucoma.

This means that instead of harming the eyes, Ozempic and Wegovy may offer a long-term protective effect.

What Patients in San Jose and Gilroy Should Do to Protect Their Vision

If you’re considering or already taking GLP-1 medications such as Ozempic or Wegovy:

• Schedule a baseline eye exam: A dilated eye check helps your doctor document the health of your retina and optic nerve before treatment. You can book an appointment at our San Jose or Gilroy office.

  
  

• Watch for changes: Report sudden flashes, floaters, or vision loss immediately. These can be symptoms of other conditions, so it's best to consult a retina specialist right away.

• Work with your care team: Your primary doctor manages your medication, while your ophthalmologist ensures your vision stays safe.

The Bottom Line: Are Ozempic and Wegovy Safe for Your Eyes?

Based on the latest evidence:

• GLP-1 medications are not strongly linked to vision loss.

• They may actually reduce the risk of glaucoma and macular degeneration progression.

• With regular eye exams and medical guidance, these medications are safe and highly beneficial for most patients.

For individuals experiencing symptoms or who are concerned about their eye health, here are some actionable steps and a clear call to action.

Immediate Action Required

If you're experiencing vision changes or have concerns about symptoms like flashes, floaters, or sudden vision loss, don't wait. Please call our clinic to schedule an appointment with a specialist.

Connect with Us!

You can reach us and learn more through the following channels:

• Website: https://www.southbayretina.com

• Phone: (408) 294-3534

• Serving: San Jose, Cupertino, and the greater South Bay Area

• 𝗬𝗼𝘂𝗧𝘂𝗯𝗲: youtube.com/@NarainEye

• 𝗜𝗻𝘀𝘁𝗮𝗴𝗿𝗮𝗺: https://www.instagram.com/south_bay_retina

• 𝗙𝗮𝗰𝗲𝗯𝗼𝗼𝗸: https://www.facebook.com/narain1

• 𝗧𝗶𝗸𝗧𝗼𝗸: https://www.tiktok.com/@southbayretina

• 𝗣𝗼𝗱𝗯𝗲𝗮𝗻: https://southbayretinamedia.podbean.com/

Bibliography / References

1. GLP-1 inhibitors and ocular complications

2. Ophthalmic Complications Associated With Semaglutide and Tirzepatide. JAMA Ophthalmology.

3. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmology.

4. Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration. PubMed.

5. GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes. JAMA Network Open.

6. Can Ozempic Affect Eye Health? Here’s What Ophthalmologists Want You to Know. American Academy of Ophthalmology.

WATCH THE VIDEO'S HERE:

LISTEN TO THE PODCAST EPISODE'S HERE: